An In-depth Review of E-2511: A Novel TrkA Positive Allosteric Modulator for Alzheimer's Disease

I. Introduction

E-2511 is an investigational small molecule drug under development by Eisai Co., Ltd..[1] It is characterized as a positive allosteric modulator (PAM) of Tropomyosin receptor kinase A (TrkA), a receptor for Nerve Growth Factor (NGF).[3] This compound is being explored for its therapeutic potential in neurodegenerative conditions, with a primary focus on Alzheimer's Disease (AD).[3] The rationale for its development stems from the critical role of neurotrophins and their receptors in neuronal survival, function, and plasticity, and the documented dysregulation of these systems in AD.[3] This report provides a comprehensive overview of E-2511, including its developing company, drug class, mechanism of action, preclinical evidence, clinical development program, and its potential role in the therapeutic landscape of AD. A critical aspect of this review involves disambiguating E-2511, the Eisai drug candidate, from other entities or codes bearing similar designations in unrelated contexts.

II. Disambiguation of "E-2511"

It is imperative to clarify that the designation "E-2511" in the context of this report refers specifically to the TrkA positive allosteric modulator developed by Eisai for neurodegenerative diseases, particularly Alzheimer's Disease.[1] The research material contains references to other entities or codes that share this or similar designations but are unrelated to the Eisai compound:

• Sodium Nitrate (E251/E 2511): Some sources refer to "E 2511" or "E 251" as an E-number for sodium nitrate (NaNO3​), a food preservative and chemical compound used in various industries.[5] This is distinct from the pharmaceutical E-2511.
• Methotrexate-related CAS numbers or identifiers: One document provides extensive chemical information for Methotrexate, including various CAS numbers and identifiers.[6] None of these are directly linked to Eisai's E-2511.
• Ethyl Cyclohexylpropanoate (CAS 2511-00-4): Other sources identify CAS number 2511-00-4 as Ethyl Cyclohexylpropanoate (also known as Poirenate), a fragrance and flavor ingredient with the IUPAC name ethyl 2-cyclohexylpropanoate and formula C11​H20​O2​.[7] This chemical is unrelated to the therapeutic agent E-2511.
• Phenmetrazine Metabolite/Analog (-)-Pseudophenmetrazine: A table within a document on Phenmetrazine lists EC50 values for various compounds, including "(-)-Pseudophenmetrazine" with a value of 2,511 nM for dopamine release inhibition.[9] This numerical value is coincidental and does not refer to the drug E-2511.
• Clinical Trial Identifiers (e.g., ECOG-ACRIN 2511, JCO Abstract 2511): Several documents mention "E2511" or "2511" as part of clinical trial identifiers (e.g., ECOG-ACRIN E2511, a Phase II trial for small cell lung cancer) or publication abstract numbers (e.g., JCO 38, 2511-2511, a study on glioblastoma).[10] These are study-specific codes and do not denote the drug E-2511 itself.

This report will exclusively focus on E-2511 as the Eisai-developed TrkA PAM for Alzheimer's Disease.

III. Drug Profile: E-2511

A. Developing Company

E-2511 is an investigational compound discovered and developed in-house by Eisai Co., Ltd., a global pharmaceutical company headquartered in Tokyo, Japan.[1] Eisai has a significant research and development pipeline, particularly in neurology and oncology, with other notable Alzheimer's disease candidates such as Lecanemab (LEQEMBI®).[2]

B. Drug Class and Target

E-2511 is classified as a small molecule drug that acts as a positive allosteric modulator (PAM) of the Tropomyosin receptor kinase A (TrkA).[3] TrkA is the high-affinity receptor for Nerve Growth Factor (NGF).[3] As a PAM, E-2511 does not directly activate TrkA by itself in the same way NGF does; instead, it binds to a site on the receptor distinct from the NGF binding site (an allosteric site) and enhances the receptor's response to NGF.[3] This modulation can lead to increased downstream signaling upon NGF binding. E-2511 is further described as a TrkA

biased positive allosteric modulator.[4]

The concept of a "biased" modulator is a sophisticated pharmacological principle. TrkA receptors, upon activation, can initiate multiple intracellular signaling cascades (e.g., PI3K/Akt, MAPK/ERK, PLCγ). A biased PAM like E-2511 may preferentially stabilize receptor conformations that favor the activation of certain downstream pathways over others. This selectivity could be therapeutically advantageous, potentially fine-tuning the cellular response to maximize neurotrophic and pro-survival signals while minimizing engagement of pathways that might lead to undesirable effects, such as pain, given TrkA's role in nociception.

C. Mechanism of Action

The mechanism of action of E-2511 revolves around its ability to positively modulate TrkA signaling, thereby potentiating the effects of NGF, particularly within the central nervous system (CNS).[3]

1. Positive Allosteric Modulation of TrkA: E-2511 directly binds to TrkA, enhancing the receptor's sensitivity and/or efficacy in response to its endogenous ligand, NGF.2 This leads to an increase in specific trophic signaling through the NGF-TrkA pathway.4 Such a mechanism aims to restore or augment a natural physiological process, which could lead to a more physiological and potentially better-tolerated therapeutic outcome compared to direct, sustained agonism.
2. Enhancement of Cholinergic Neuron Function and Reinnervation: A key consequence of enhanced TrkA signaling is the support and potential restoration of cholinergic neurons. NGF is crucial for the survival, maintenance, and function of these neurons, especially in the basal forebrain, which are significantly affected in AD.4 Preclinical studies suggest E-2511 has the potential to recover and promote the reinnervation of damaged cholinergic neurons, thereby activating cholinergic functions.4 This was highlighted in non-clinical studies where E-2511 was shown to reinnervate cholinergic neurons and activate cholinergic functions 13 (Abstract #62590).
3. Modulation of Synaptic Pathways and CSF Biomarkers: E-2511's action extends to broader effects on synaptic health. It has been demonstrated to modulate proteins and gene expression related to neurotrophin/Trk signaling and synaptic pathways.4 Early clinical studies in healthy volunteers (specifically, the E2511-A001-005 study) have shown that E-2511 administration leads to changes in cerebrospinal fluid (CSF) biomarkers associated with these pathways, indicating target engagement and downstream biological effects in the CNS.2
4. Distinction from Other AD Drug Mechanisms (e.g., Cholinesterase Inhibitors): The mechanism of E-2511 is distinct from that of existing symptomatic treatments for AD, such as cholinesterase inhibitors (ChEIs) like donepezil. ChEIs primarily act by inhibiting the breakdown of acetylcholine, thereby increasing its availability in the synaptic cleft. In contrast, non-clinical studies indicate that E-2511's effects on gene expression related to cholinergic, neurotrophin/Trk, and synaptic pathways are mediated via NGF-TrkA signal activation. Donepezil, despite increasing acetylcholine levels, failed to elicit similar effects on these candidate biomarkers in comparative preclinical models.4 This suggests E-2511 may offer a more fundamental, potentially neurorestorative approach rather than solely symptomatic relief through neurotransmitter modulation.

D. Note on Specific Chemical Identity

While the pharmacological class, target, and mechanism of E-2511 are well-described, the precise chemical structure or IUPAC name of Eisai's E-2511 is not explicitly provided in the available research documents focusing on this specific therapeutic agent.[1] The chemical details provided in some documents pertain to unrelated substances like sodium nitrate or ethyl cyclohexylpropanoate, as clarified in Section II.[5]

IV. Rationale and Therapeutic Potential in Alzheimer's Disease

A. The Role of Neurotrophins and TrkA Signaling in AD Pathophysiology

Neurotrophins, particularly NGF and Brain-Derived Neurotrophic Factor (BDNF), and their cognate Trk receptors (TrkA for NGF, TrkB for BDNF) are fundamental regulators of neuronal development, survival, function, and synaptic plasticity.[3] Their role in maintaining brain health is critical, and disruptions in neurotrophin signaling are increasingly recognized as significant contributors to the pathophysiology of AD.[3]

NGF-TrkA signaling is particularly vital for the health of basal forebrain cholinergic neurons, which provide widespread cholinergic innervation to the cortex and hippocampus—regions crucial for learning and memory.[4] A decline in NGF trophic support and subsequent degeneration of these cholinergic neurons are early and prominent features of AD, correlating strongly with cognitive decline.[4] Attempts to directly administer neurotrophins like NGF to patients have faced substantial hurdles, including poor blood-brain barrier penetration and significant side effects, which has shifted focus towards small molecule modulators like E-2511 that can overcome these limitations.[3]

B. Potential for E-2511 to Offer Symptomatic Relief and Disease-Modifying Effects

The mechanism of E-2511 as a TrkA PAM suggests a dual therapeutic potential in AD. By enhancing NGF-TrkA signaling, E-2511 could:

1. Provide symptomatic relief by improving the function of surviving cholinergic neurons and potentially enhancing cognitive processes reliant on cholinergic transmission.[3]
2. Offer disease-modifying effects by promoting the survival of vulnerable neurons, stimulating neurorestorative processes such as synaptic remodeling and reinnervation of damaged cholinergic neurons, and potentially slowing the neurodegenerative cascade.[3]

Preclinical data lend support to this dual potential, with reports of disease-modifying effects in animal models and indications of a neurorestorative function.[3] This approach targets the underlying neurobiology of degeneration rather than just the neurotransmitter deficits, which is a key aspiration for next-generation AD therapies.

C. Positioning Relative to Other AD Therapeutic Strategies

The therapeutic landscape for AD is evolving, with several strategies being pursued. E-2511's neurotrophic approach offers a distinct or complementary mechanism to other modalities:

• Anti-Amyloid Monoclonal Antibodies: Drugs like Lecanemab (also from Eisai) target the removal of amyloid-beta plaques, one of the hallmark pathologies of AD.[2] While these agents have shown modest slowing of cognitive decline, there remains a significant unmet need for therapies that can protect neurons from downstream damage or restore lost function. E-2511 could complement such therapies by providing neurotrophic support to neurons stressed by the amyloid pathology or other disease processes.[3]
• Cholinesterase Inhibitors (ChEIs): As discussed, ChEIs provide symptomatic benefit by increasing acetylcholine levels. E-2511, by potentially restoring the health and connectivity of cholinergic neurons themselves, could offer a more upstream and potentially more profound or sustained benefit.[4]

The development of TrkA PAMs like E-2511 signifies an expansion in AD therapeutic strategies beyond the primary focus on amyloid and tau. While these proteinopathies are critical targets, addressing downstream consequences such as neurodegeneration, synaptic loss, and specific neurotransmitter system failure is equally important for comprehensive treatment. E-2511's distinct mechanism could make it suitable for combination therapies, attacking AD from multiple angles, or as a standalone treatment for specific patient populations.

V. Preclinical Evidence Supporting E-2511

A. Summary of Key In Vitro and In Vivo Findings

Preclinical investigations have provided foundational support for the therapeutic concept of E-2511. These studies, conducted in various cellular and animal models, have demonstrated that E-2511 engages its target, TrkA, and elicits biological responses consistent with enhanced neurotrophic signaling.[3]

B. Evidence of Neurorestorative Effects and Cognitive Benefits

A significant body of preclinical work points towards E-2511's potential neurorestorative capabilities. Studies have indicated that E-2511 can promote the recovery and reinnervation of damaged cholinergic neurons.[4] For instance, in animal models, including human Tau P301S transgenic mice (which recapitulate aspects of tau pathology seen in AD), E-2511 administration for 3 months was shown to induce functional restoration of cholinergic neurons.[19] This suggests that E-2511's neuroprotective and restorative effects might be relevant even in the context of tau-driven pathology. The compound has been reported to have disease-modifying effects and a tentative neurorestorative function in preclinical models, potentially leading to synaptic remodeling and improved neuronal function.[3] While direct reports on cognitive enhancement in animal models for E-2511 are less detailed in the provided materials compared to its peer ACD856 [17], the focus on cholinergic neuron restoration implies a potential for cognitive benefits.

C. Biochemical and Gene Expression Changes Indicative of Target Engagement and Pathway Activation

Non-clinical studies, particularly in rats, have shed light on the molecular changes induced by E-2511. Oral administration of E-2511 for 14 days led to increased gene expression of several candidate pharmacodynamic (PD) biomarkers related to the cholinergic pathway, neurotrophin/Trk signaling, and synaptic pathways in the septum, a basal forebrain region rich in cholinergic neurons.[4]

Crucially, these gene expression changes induced by E-2511 were not replicated by treatment with the cholinesterase inhibitor donepezil, even though donepezil effectively increased acetylcholine levels.4 This finding underscores that E-2511's mechanism is not simply an alternative way to boost cholinergic tone but involves a more fundamental engagement of NGF-TrkA signal activation and downstream neurotrophic and synaptic plasticity pathways. Such upstream action could translate to broader and more sustained therapeutic benefits compared to ChEIs alone by directly influencing neuronal health, structure, and function.

VI. Clinical Development Program of E-2511

A. Overview of Clinical Trials

E-2511 has progressed into clinical development, with Phase 1 studies completed or underway to assess its safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) in humans.[2] These initial trials are crucial for establishing a foundation for further investigation in AD patients. It is important to distinguish the drug E-2511 from unrelated clinical trial identifiers like "ECOG-ACRIN 2511" or abstract numbers such as "2511" which refer to different studies, often in oncology.[10]

B. Key Phase 1 Study: E2511-A001-005 (Multiple-Ascending Dose Study in Healthy Volunteers)

A key study in the early clinical development of E-2511 is the E2511-A001-005 trial, a multiple-ascending dose (MAD) study conducted in healthy volunteers.[4] The general design of such Phase 1 studies typically involves several cohorts of participants receiving escalating doses of the investigational drug or placebo to determine the safety and tolerability profile over a range of exposures.[20] The E2511-A001-005 study specifically utilized pre- and post-treatment CSF samples to identify novel candidate PD biomarkers using multi-platform global proteomic approaches.[4] The use of such comprehensive, unbiased proteomic analyses in Phase 1 suggests a commitment to deeply understanding the drug's biological impact in the CNS early in development, potentially leading to novel insights beyond pre-specified biomarkers.

The successful completion of MAD studies is a critical milestone, establishing an initial human safety window and providing essential dosing information for subsequent trials in patient populations.

The table below summarizes the typical design and objectives of a Phase 1 study for a compound like E-2511, based on the information available for E2511-A001-005 and general Phase 1 study designs for CNS drugs.

Feature	Description	Data Sources
Study Identifier (Example)	E2511-A001-005	4
Study Phase	Phase 1	2
Primary Objective(s)	To assess the safety and tolerability of single and/or multiple ascending doses of E-2511.	3
Secondary/Exploratory Objective(s)	To evaluate the pharmacokinetics (PK) of E-2511. To identify and measure pharmacodynamic (PD) biomarkers in CSF, including those related to cholinergic, neurotrophin/Trk, and synaptic pathways.	4
Participant Population	Healthy adult volunteers (often including elderly cohorts for AD drugs).	4
Dosing Regimen	Single Ascending Dose (SAD) and/or Multiple Ascending Dose (MAD) cohorts; oral administration.	4
Key Reported Outcomes	Incidence of adverse events, PK parameters (e.g., Cmax​, AUC, t1/2​), changes in CSF protein/gene expression biomarkers.	2

C. Key Findings from Phase 1 Studies

1. Safety and Tolerability Profile: E-2511 has been reported to be safe and well-tolerated in Phase 1 clinical studies involving healthy subjects.3 This is a critical finding, as a favorable safety profile is paramount for drugs intended for chronic administration in an often elderly and vulnerable AD population. It is important to note that safety information for unrelated drugs like Erivedge 21 or general discussions on chemotherapy-induced nausea 22 are not applicable to E-2511.
2. Pharmacokinetic (PK) Characteristics: E-2511 is an orally administered small molecule. Pharmacokinetic data from Phase 1 studies indicate that E-2511 has a relatively short plasma half-life (t1/2​) of approximately 3.2 hours.17 This is in contrast to another Trk PAM, ACD856, which has a reported half-life of around 20 hours.3 A short half-life like that of E-2511 might necessitate multiple daily doses (e.g., twice or thrice daily) to maintain steady-state therapeutic concentrations in the CNS. This could have implications for patient adherence and might drive the development of modified-release formulations in later stages of development to improve convenience.
3. Evidence of CNS Target Engagement and Modulation of CSF Biomarkers: A key outcome from the Phase 1 program, particularly the E2511-A001-005 study, is the demonstration of CNS target engagement. Data presented from this study showed that E-2511 modulates CSF biomarkers related to the cholinergic pathway, neurotrophin/Trk signaling, and synaptic pathways in healthy volunteers.4 Furthermore, it was reported that E-2511 engages its CNS cholinergic target in a Phase 1 clinical study.2 These findings are significant as they provide early human evidence that E-2511 reaches the CNS at active concentrations and exerts measurable biological effects consistent with its proposed mechanism of action.

D. Current Clinical Status and Future Directions

As of late 2023, E-2511 was reported to be actively in Phase 1 development.[2] The positive safety findings and evidence of target engagement and pathway activation in healthy volunteers are supportive of continued development.[4] The logical next step would be the initiation of Phase 2 trials in patients with Alzheimer's Disease. These studies would aim to evaluate the efficacy of E-2511 in improving cognitive symptoms and potentially modifying disease progression biomarkers in the target patient population, while further characterizing its safety profile.

VII. Concluding Remarks and Future Outlook

A. Summary of E-2511's Profile and Potential Significance

E-2511, developed by Eisai, is an orally available, small molecule, biased positive allosteric modulator of TrkA. Its mechanism of action, centered on enhancing endogenous NGF signaling, represents a novel therapeutic strategy for Alzheimer's Disease.[3] By potentially promoting cholinergic neuron health, synaptic function, and offering neurorestorative effects, E-2511 holds the promise of delivering both symptomatic improvement and disease-modifying benefits.[3] This approach, targeting neurotrophic pathways, is distinct from many current and past AD therapeutic strategies.

B. Discussion of its Novel Approach in the Context of AD Treatment

The pursuit of TrkA PAMs like E-2511 reflects a growing understanding of the multifaceted nature of AD pathology and the need for therapeutic approaches that go beyond amyloid and tau clearance. Enhancing endogenous neuroprotective and neurorestorative mechanisms, such as NGF-TrkA signaling, could provide a valuable complement or alternative to therapies focused on removing pathological protein aggregates.[3] The development of E-2511 as a small molecule PAM also represents a more drug-like strategy to harness the therapeutic potential of the NGF-TrkA pathway, overcoming the significant challenges associated with direct NGF administration.[3]

The parallel development of E-2511 (a selective TrkA PAM) and other compounds like ACD856 (a pan-Trk PAM) by different entities indicates a broader validation of Trk receptors as druggable targets for neurodegenerative disorders.[3] This concurrent research may provide valuable comparative insights into the relative merits of selective versus broader Trk modulation.

C. Considerations for Further Development and Potential Impact

The journey of E-2511 from preclinical promise to a clinically effective AD therapy is still in its early stages and faces the considerable challenges inherent in AD drug development. The successful translation of CSF biomarker changes observed in healthy volunteers into tangible clinical benefits in AD patients in Phase 2 and Phase 3 trials will be the critical determinant of its future.[2] Issues such as optimal dosing, long-term safety, and the ability to demonstrate clinically meaningful efficacy in a heterogeneous patient population will need to be addressed.

However, given the high unmet medical need for effective AD treatments, particularly those that can modify the disease course and improve neuronal function, E-2511 represents an important and innovative candidate. If its potential is realized, E-2511 could offer a significant new therapeutic option for individuals suffering from Alzheimer's Disease, potentially as a standalone therapy or in combination with other emerging treatments. The continued development and rigorous clinical evaluation of E-2511 are therefore keenly anticipated.

Works cited

1. E2511 / Eisai - LARVOL DELTA, accessed June 13, 2025, https://delta.larvol.com/Products/?ProductId=4a690715-7118-42bb-a622-38d125e4ed89
2. Eisai To Present New Data From Leqembi (Lecanemab-irmb) Phase 3 Clarity AD Study And Other Alzheimer's Disease Pipeline Research At The Clinical Trials On Alzheimer's Disease (CTAD) Conference - FirstWord Pharma, accessed June 13, 2025, https://firstwordpharma.com/story/5790027
3. E2511 - Drug Targets, Indications, Patents - Synapse, accessed June 13, 2025, https://synapse.patsnap.com/drug/1c6ebb3311bb43089f9bf49e57f9a426
4. Non‐clinical evidence for modulating synaptic CSF biomarkers by E2511, a novel small molecule TrkA biased positive allosteric modulator, accessed June 13, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC11712391/
5. E 2511 | Sodium Nitrate Uses and Safety - Ontosight | AI, accessed June 13, 2025, https://ontosight.ai/glossary/term/sodium-nitrate-uses-and-safety--67a190056c3593987a58b421
6. Methotrexate | C20H22N8O5 | CID 126941 - PubChem, accessed June 13, 2025, https://pubchem.ncbi.nlm.nih.gov/compound/Methotrexate
7. CAS No.2511-00-4,ETHYL CYCLOHEXYL PROPIONATE Suppliers - LookChem, accessed June 13, 2025, https://www.lookchem.com/cas-251/2511-00-4.html
8. ethyl 2-cyclohexyl propionate poirenate - The Good Scents Company, accessed June 13, 2025, http://www.thegoodscentscompany.com/data/rw1043591.html
9. Phenmetrazine - Wikipedia, accessed June 13, 2025, https://en.wikipedia.org/wiki/Phenmetrazine
10. Patient‐reported tolerability of veliparib combined with cisplatin and etoposide for treatment of extensive stage small cell lung cancer: Neurotoxicity and adherence data from the ECOG ACRIN cancer research group E2511 phase II randomized trial - PMC, accessed June 13, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC7571824/
11. Randomized Phase II Trial of Cisplatin and Etoposide in Combination With Veliparib or Placebo for Extensive-Stage Small-Cell Lung Cancer: ECOG-ACRIN 2511 Study - PMC - National Institutes of Health (NIH) |, accessed June 13, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC6338394/
12. Phase I/II study to evaluate the safety and clinical efficacy of atezolizumab (atezo; aPDL1) in combination with temozolomide (TMZ) and radiation in patients with newly diagnosed glioblastoma (GBM). - ASCO Publications, accessed June 13, 2025, https://ascopubs.org/doi/10.1200/JCO.2020.38.15_suppl.2511
13. EISAI TO PRESENT THE LATEST LECANEMAB DATA, INCLUDING ARIA-E AND SUBCUTANEOUS FORMULATION, AND OTHER ALZHEIMER'S DISEASE RESEARCH AT THE ALZHEIMER'S ASSOCIATION INTERNATIONAL CONFERENCE (AAIC) 2022 | News Release, accessed June 13, 2025, https://www.eisai.com/news/2022/news202257.html
14. News Release：2023 | Eisai Co., Ltd., accessed June 13, 2025, https://www.eisai.com/news/2023/index.html
15. Latest Major R&D Pipeline | Research and Development (R&D) | Eisai Co., Ltd., accessed June 13, 2025, https://www.eisai.com/innovation/research/pipeline/index.html
16. EP3919490B1 - Five-and-six-membered heterocyclic compound and use thereof as protein receptor kinase inhibitor - Google Patents, accessed June 13, 2025, https://patents.google.com/patent/EP3919490B1/en
17. Positive Allosteric Modulator of Trk- receptors for the Treatment of Alzheimer's Disease - AlzeCure Pharma, accessed June 13, 2025, https://www.alzecurepharma.se/sv/wp-content/uploads/sites/3/2025/01/neurorestore-article-review-presentation-dec-2024.pdf
18. CTAD ABSTRACT 2023 oct 24_compressed.pdf - CTAD Alzheimer, accessed June 13, 2025, https://www.ctad-alzheimer.com/files/files/CTAD%20ABSTRACT%202023%20oct%2024_compressed.pdf
19. (PDF) Non‐clinical evidence for modulating synaptic CSF biomarkers by E2511, a novel small molecule TrkA biased positive allosteric modulator - ResearchGate, accessed June 13, 2025, https://www.researchgate.net/publication/387857553_Non-clinical_evidence_for_modulating_synaptic_CSF_biomarkers_by_E2511_a_novel_small_molecule_TrkA_biased_positive_allosteric_modulator
20. A Study to Assess the Safety and Tolerability of E2511 in Healthy Participants, accessed June 13, 2025, https://ctv.veeva.com/study/a-study-to-assess-the-safety-and-tolerability-of-e2511-in-healthy-participants
21. Erivedge Side Effects & Tips, accessed June 13, 2025, https://www.erivedge.com/hcp/side-effects/summary.html
22. Nausea and Vomiting Related to Cancer Treatment (PDQ®)–Health Professional Version, accessed June 13, 2025, https://www.cancer.gov/about-cancer/treatment/side-effects/nausea/nausea-hp-pdq
23. EISAI TO PRESENT NEW DATA FROM LEQEMBI® (LECANEMAB-IRMB) PHASE 3 CLARITY AD STUDY AND OTHER ALZHEIMER'S DISEASE PIPELINE RESEARCH AT THE CLINICAL TRIALS ON ALZHEIMER'S DISEASE (CTAD) CONFERENCE | News Release：2023, accessed June 13, 2025, https://www.eisai.com/news/2023/news202365.html